|
MDC asks Abbott Healthcare to avoid negligence while filing price details in IPDMS
|
|
Gireesh Babu, New Delhi
August 12 , 2025
|
|
|
The Multi Disciplinary Committee (MDC) of Experts, which advises the National Pharmaceutical Pricing Authority (NPPA) on pricing matters, has directed Abbott Healthcare to avoid negligence in filing proper details while submitting the price related details in the Integrated Pharmaceutical Database Management System (IPDMS).
The Committee also recommended a revised price for the company's anti-bacterial drug clarithromycin 1000 mg, after the company informed that it had incorrectly stated a lower price for the drug while filling the Form I on IPDMS, owing to a typographical error.
The MDC has in its meeting on July 3, 2025, fixed the retail price of the formulation at Rs. 13 per tablet, considering it as the lower of the claimed price as against the worked out price of Rs. 71.71. The price was worked out by the Committee after applying the Pronob Sen formula on the ceiling price of clarithromycin tablet 500 mg (Rs. 39.84 per tablet) applicable on six months prior to the date of application, that is November 2024.
However, the company on July 16, submitted a representation that there was a typographical error in their Form I submission on IPDMS and claimed price was incorrectly stated as Rs. 13 per tablet (Rs. 91 per strip of seven tablets) instead of the correct Rs. 91 per tablet.
The MDC, in its latest meeting, noted that the ceiling price for clarithromycin tablets 250 mg and 500 mg applicable on six months prior to date of application, that is November 2024 was Rs. 23.89 and Rs. 39.84 per tablet respectively. There is no other company marketing the applied formulation, it observed.
"Committee noted the serious error committed by the applicant and recommended the retail price for each extended-release film coated tablet contains: Clarithromycin IP 1000 mg at Rs. 71.71 per tablet, as worked out by applying the Pronab Sen formula.....," said MDC after its latest meeting.
"The committee also directed the applicant to ensure avoiding such negligence which could affect the committee deliberations and unnecessarily delay the disposal of Form I applications," it added.
The Committee has earlier noted that the data for clarithromycin IP 1000 mg extended release tablets is not available in the Pharmarack database of May, 2025. It noted that the company had claimed a price of Rs. 13 per tablet excluding tax.
The Committee observed the retail price data for the clarithromycin IP 1000 mg ER tablets using the formula recommended in the Pronab Sen Committee report comes to Rs. 71.71 per tablet (excluding taxes).
Clarithromycin is used for the treatment of bacterial infections such as of tonsils, sinus, skin and lungs, among others, according to online pharmacy 1 mg.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|